277 related articles for article (PubMed ID: 25242511)
1. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.
Wouters R; Cucchi D; Kaspers GJ; Schuurhuis GJ; Cloos J
Expert Rev Hematol; 2014 Dec; 7(6):791-805. PubMed ID: 25242511
[TBL] [Abstract][Full Text] [Related]
2. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.
Hoang VT; Zepeda-Moreno A; Ho AD
Biotechnol J; 2012 Jun; 7(6):779-88. PubMed ID: 22588704
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
4. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
5. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
Hagenbeek A; Martens AC
Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
[TBL] [Abstract][Full Text] [Related]
6. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
7. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
[No Abstract] [Full Text] [Related]
8. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
Jorgensen JL; Chen SS
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
[TBL] [Abstract][Full Text] [Related]
10. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
12. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Majeti R
Best Pract Res Clin Haematol; 2014; 27(3-4):229-34. PubMed ID: 25455271
[TBL] [Abstract][Full Text] [Related]
13. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
14. Leukemia stemness signatures step toward the clinic.
Becker MW; Jordan CT
Cell Stem Cell; 2011 Sep; 9(3):185-6. PubMed ID: 21885015
[TBL] [Abstract][Full Text] [Related]
15. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.
Hoang VT; Hoffmann I; Borowski K; Zepeda-Moreno A; Ran D; Buss EC; Wuchter P; Eckstein V; Ho AD
Methods Mol Biol; 2013; 1035():217-30. PubMed ID: 23959995
[TBL] [Abstract][Full Text] [Related]
16. Transformation from committed progenitor to leukemia stem cells.
Krivtsov AV; Feng Z; Armstrong SA
Ann N Y Acad Sci; 2009 Sep; 1176():144-9. PubMed ID: 19796242
[TBL] [Abstract][Full Text] [Related]
17. Leukemia stem cells in 2010: current understanding and future directions.
Becker MW; Jordan CT
Blood Rev; 2011 Mar; 25(2):75-81. PubMed ID: 21216511
[TBL] [Abstract][Full Text] [Related]
18. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
19. Stem cell niche as a prognostic factor in leukemia.
Lee GY; Kim JA; Oh IH
BMB Rep; 2015 Aug; 48(8):427-8. PubMed ID: 26198094
[TBL] [Abstract][Full Text] [Related]
20. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry.
Terstappen LW; Loken MR
Anal Cell Pathol; 1990 Jul; 2(4):229-40. PubMed ID: 1703434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
